Korsana Biosciences, Inc.
KRSA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 43.2%, EPS fell 272.7% and free cash flow fell 184.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow KRSA
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more quarters Free account |
(0.98) | (0.80) | (3.18) | (1.75) |
Non Cash Items (Other) |
0.12 | 0.10 | 0.06 | 0.05 | |
Accounts Receivable Change |
0.43 | (0.90) | 1.00 | 0.00 | |
Accounts Payable Change |
0.02 | 0.03 | (0.05) | 1.14 | |
Change in other assets and liabilities |
0.15 | 0.00 | 0.99 | (0.87) | |
Operating Cash Flow |
(0.26) | (1.58) | (1.18) | (1.43) | |
Capital expenditures |
— | — | (0.07) | 0.00 | |
Investing cash flow |
0.00 | — | (0.07) | 0.00 | |
Other financial activities |
1.83 | 0.25 | 0.83 | 0.00 | |
Financing cash flow |
1.83 | 0.25 | 0.83 | 0.00 | |
Change in Cash |
1.56 | (1.33) | (0.42) | (1.43) | |
Beginning Cash |
0.00 | 0.00 | 3.24 | 0.00 | |
Ending Cash |
1.56 | (1.33) | 2.82 | (1.43) | |
Stock Based Compensation |
0.12 | 0.10 | 0.06 | 0.05 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash/Marketcap |
0.00 | 0.00 | — | — | |
Assets Liabilities Change (Total) |
0.59 | (0.87) | 1.94 | 0.27 |